Optimización de la triple terapia en el tratamiento del cáncer de próstata hormonosensible metastásico

IF 1.2 4区医学 Q3 UROLOGY & NEPHROLOGY

Actas urologicas espanolas Pub Date : 2024-12-01 DOI:10.1016/j.acuro.2024.07.003

A. Borque-Fernando , D.A. Pérez-Fentes , M. Rodrigo-Aliaga , J. Puente-Vázquez , A. Gómez-Iturriaga , M. Unda , M.A. Calleja-Hernández , J.M. Cózar-Olmo , J.L. Álvarez-Ossorio

{"title":"Optimización de la triple terapia en el tratamiento del cáncer de próstata hormonosensible metastásico","authors":"A. Borque-Fernando , D.A. Pérez-Fentes , M. Rodrigo-Aliaga , J. Puente-Vázquez , A. Gómez-Iturriaga , M. Unda , M.A. Calleja-Hernández , J.M. Cózar-Olmo , J.L. Álvarez-Ossorio","doi":"10.1016/j.acuro.2024.07.003","DOIUrl":null,"url":null,"abstract":"<div><div>Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"48 10","pages":"Pages 703-717"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480624001153","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.

查看原文本刊更多论文

优化激素敏感转移性前列腺癌的三联疗法

多西紫杉醇、雄激素剥夺疗法（ADT）和雄激素受体途径抑制剂（arpi）的三联疗法已证明可改善转移性激素敏感前列腺癌（mHSPC）患者的生存，尤其是那些高风险疾病患者。然而，一旦确定了ADT和多西他赛的使用，指南并没有明确规定哪种ARPI是最合适的。在这项工作中，进行了文献综述，以确定mHSPC三联疗法的III期临床试验、系统评价、荟萃分析和临床实践指南。对证据和建议进行定性审查，以根据患者风险、疾病体积和转移性质（同步或异时性）提供最合适的ARPI指南。本综述旨在更新先前发表的关于mHSPC最佳药物治疗的共识，并揭示医院药学、泌尿科、医学和放射肿瘤学专家的意见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

46 days

期刊介绍： Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.